MYD88 and serum lipopolysaccharide activity: It improved AOM/DSS-induced microbial dysbiosis, increased the production of short-chain fatty acids, alleviated endotoxemia, and improved intestinal shielding function by inhibiting TLR4/MyD88/NF-κB signaling.